Tokyo, Japan and Cambridge, UK, 23 October 2024 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) – formerly known as Sosei Group or Sosei Heptares – is pleased to announce that it has won ...
Bronchiectasis is a clinical condition defined as a chronic, abnormal dilation of the bronchi accompanied by classical ...
Progressive pulmonary fibrosis (PPF) is an increasingly recognised condition, defined in 2022 to address the progression of ...
Prior to Exelixis, she spent over 10 years at Boehringer Ingelheim Pharmaceuticals, Inc. focused on pipeline expansion and discovery in positions including senior vice president, global head of ...
GlobalData on MSN8d
Boehringer partners WHO Foundation to advance healthcare accessBoehringer Ingelheim, in partnership with the WHO Foundation [an organisation set up to support the World Health Organization ...
Boehringer Ingelheim, a biopharmaceutical company active in both human and animal health, in partnership with WHO Foundation, today pledged USD 5 million to advance access to quality healthcare servic ...
An investigational oral fatty acid synthase (FASN) inhibitor was associated with significant improvements in metabolic ...
As Hurricane Milton made landfall in Florida Wednesday night, drugmakers, regulators, hospitals and health agencies alike ...
GSK has agreed to pay up to $2.2 billion to settle most lawsuits in U.S. state courts claiming that a discontinued version of ...
GlobalData on MSN13d
Boehringer and Circle Pharma link to develop new cancer treatmentBoehringer Ingelheim and Circle Pharma have entered a new research partnership and licence agreement to develop a new ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback